Loading...
Loading...
BLRX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 8,398.0K |
| Operating I/L | -8,398.0K |
| Other Income/Expense | 2,667.0K |
| Interest Income | 438.0K |
| Pretax | -5,731.0K |
| Income Tax Expense | -2,667.0K |
| Net Income/Loss | -3,064.0K |
BioLineRx Ltd. is a clinical-stage biopharmaceutical development company specializing in oncology. The company's primary focus is on the development of Motixafortide, a peptide with applications in autologous stem cell mobilization, pancreatic cancer, metastatic pancreatic adenocarcinoma, acute respiratory distress syndrome, and solid tumors. Additionally, the company is developing AGI-134, an immuno-oncology agent for the treatment of solid tumors, and BL-5010, a pen-like applicator for non-surgical removal of skin lesions. BioLineRx has collaboration agreements with MSD and MD Anderson Cancer Center, as well as a licensing arrangement with Perrigo Company plc for the over-the-counter sale of BL-5010.
